New products introduced over the last week include a new small-cap dividend growth fund from WisdomTree and a new odd-lot fixed income pricing service from BondDesk and S&P Capital IQ. In addition, Direxion announced reverse and forward share splits for nine of its ETFs, and Allianz Global Investors said it will develop a global emerging market debt capability.
Here are the latest developments of interest to advisors:
1) WisdomTree Launches U.S. SmallCap Dividend Growth Fund
WisdomTree announced Thursday the launch of the WisdomTree U.S. SmallCap Dividend Growth Fund (DGRS), designed to provide exposure to small-cap dividend-paying stocks with growth characteristics; it has an expense ratio of 0.38%.
DGRS seeks to offer a diversified basket of small-cap dividend-paying securities with growth characteristics; differentiated exposure from traditional dividend funds; greater exposure to cyclical sectors leveraged to an improving U.S. economy, versus more defensive sectors; having at annual index rebalance a single stock cap of 2% and a sector cap of 25%.
Best Cheapest Companies For 2015: Cynosure Inc.(CYNO)
Cynosure, Inc. develops, manufactures, and markets aesthetic treatment systems to the dermatology, plastic surgery, and general medical markets. Its aesthetic treatment systems incorporate a range of laser and other light-based energy sources, including Alexandrite, pulse dye, Nd:Yag, and diode lasers, as well as intense pulsed light. The company?s aesthetic treatment systems comprise the Elite product line for hair removal, treatment of facial, and leg veins and pigmentations; the Smartlipo product line for LaserBodySculpting for the removal of unwanted fat; the Cellulaze, SmoothShapes XV, and TriActive product line for the temporary and long-term reduction in the appearance of cellulite; the Affirm/SmartSkin product line for anti-aging applications, such as treatments for wrinkles, skin texture, skin discoloration, and skin tightening; the Cynergy product line for the treatment of vascular lesions; and the Accolade product line for the removal of benign pigmented lesion s, as well as multi-colored tattoos. It sells its products through a direct sales force in North America, France, Spain, the United Kingdom, Germany, Korea, China, Japan, and Mexico; and through international distributors in 84 other countries. Cynosure, Inc. was founded in 1991 and is based in Westford, Massachusetts.
Advisors' Opinion:- [By Rich Duprey]
Aesthetic-laser maker Cynosure (NASDAQ: CYNO ) announced yesterday that it had completed the acquisition of rival laser specialist Palomar Medical Technologies for $146 million cash and 6 million shares for a total value of around $294 million.
Hot Defensive Companies To Invest In Right Now: Merck & Company Inc.(MRK)
Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company?s Pharmaceutical segment provides human health pharmaceutical products, such as therapeutic and preventive agents for the treatment of human disorders in the areas of bone, respiratory, immunology, dermatology, cardiovascular, diabetes and obesity, infectious diseases, neurosciences and ophthalmology, oncology, vaccines, and women's health and endocrine. This segment also offers human health vaccines, such as preventive pediatric, adolescent, and adult vaccines. Its Animal Health segment discovers, develops, manufactures, and markets animal health products. This segment offers antibiotics, anti-inflammatory products, vaccines, products for the treatment of fertility disorders, and parasiticides for cattle, swine, horses, poultry, dogs, cats, salmons, and fish. The Consumer Care segment develops, manufac tures, and markets over-the-counter, foot care, and sun care products. Its over-the-counter product line includes non-drowsy antihistamines; treatment for occasional constipation; decongestant-free cold/flu medicine for people with high blood pressure; nasal decongestant spray; and treatment for frequent heartburn. This segment?s foot care products comprise topical antifungal, and foot and sneaker odor/wetness products; and sun care products include sun care lotions, sprays and dry oils; and sunburn relief products. The company serves drug wholesalers and retailers, hospitals, government agencies, physicians, physician distributors, veterinarians, animal producers, and managed health care providers, as well as food chain and mass merchandiser outlets in the United States and Canada. Merck & Co., Inc. was founded in 1891 and is headquartered in Whitehouse Station, New Jersey.
Advisors' Opinion:- [By Dan Caplinger]
In writing about the Dow's pharmaceutical components this morning, I had no idea they would eventually prove to be the stars of today's session. But Merck (NYSE: MRK ) and Pfizer (NYSE: PFE ) both rose almost 3% today, because of a combination of company-specific news and general bullishness on the two dividend giants. Pfizer announced that its palbociclib experimental treatment for advanced breast cancer received FDA designation as a breakthrough drug, which should help it earn an expedited development and review schedule as Pfizer plans appropriate research for the drug.
- [By Sean Williams]
This week saw two new drugs approved by the FDA: Raptor Pharmaceuticals' (NASDAQ: RPTP ) Procysbi and Merck's (NYSE: MRK ) Liptruzet.
- [By Henry Kawabe]
Biopharmaceutical company Endocyte (ECYT) reported a second quarter 2013 net loss of 23 cents per share, which amounted to almost three times the loss of Zacks Consensus Estimate of 8 cents per share, and a larger loss compared to the same quarter the previous year; the stock did not experience a decline. It appears as though investors have maintained confidence in the company whose stock has more than doubled over the past year. And I believe there are good reasons for such confidence in the company, and the stock. The first reason is its pipeline of drugs led by its flagship proprietary technology novel small molecule drug conjugates (SMDCs) that actively target receptors that are over-expressed on cancer cells relative to healthy cells. And the second reason is that the SMDC technology has led to its collaboration with Merck (MRK) on a cancer treatment vintafolide (EC145) that has the potential to net Endocyte $1 billion.
Hot Defensive Companies To Invest In Right Now: Yelp Inc (YELP)
Yelp Inc., incorporated on September 03, 2004, connects people with great local businesses. Its users have contributed a total of approximately 36.0 million cumulative reviews of almost every type of local business, from restaurants, boutiques and salons to dentists, mechanics and plumbers. Its platform provides local businesses with a range of free and paid services, which help them to engage with consumers at moment when they are deciding where to spend their money. The Company generates revenue from local advertising, brand advertising and other services. As of December 31, 2012, the Company was active in 53 Yelp markets in the United States and 44 Yelp markets internationally. Effective July 18, 2013, Yelp Inc acquired SeatMe Inc, which is a developer of restaurant and nightlife categories reservation applications.
Local Business
The Company enables businesses to create a free online business account and claim the page for each of their business locations. Business representatives can verify their affiliation with the business through an automated telephone verification process, which requires that they be reachable at the phone number, which is publicly displayed for their business listing on its platform. With their free business accounts, businesses can view business trends, message customers, update information and offer Yelp Deals. Its listing solution eliminates search advertising from the businesses��profile pages and allows them to incorporate a video clip or photo slide show on the pages. It allows local businesses to promote themselves as a sponsored search result on its platform or on related business pages.
The Company�� Yelp Deals product allows local business owners to create promotional discounted deals for their products and services, which are marketed to consumers through its platform. Yelp Deals have a fee structure based solely on transaction volume with no upfront costs, and it earns a fee based on the discounted price of each deal so! ld. It processes all customer payments and remits to the business the revenue share of any Yelp Deal purchased. It offers both e-mail deals, which are focused on demand generation and deals on its platform that are focused on demand fulfillment where businesses can target intent-driven consumers who are specifically searching for a product or service on its platform.
The Company�� Gift Certificates product allows local business owners to sell full price gift certificates directly to customers through their business profile page. The business chooses the price points to offer, and the buyer may purchase a Gift Certificate in one of those amounts. The Company earns a fee based on the amount of the Gift Certificate sold. The Company processes all consumer payments and remit to the business the revenue share of any Gift Certificate purchased.
National/Brand Advertisers
The Company offers its advertising solution for national brands that want to improve their local presence. These solutions consist of search and display ads (both graphic and text) on its Website, which are typically sold to advertisers on a per-impression basis. Its national advertisers include brands in the automobile, financial services, logistics, consumer goods and health and fitness industries.
Transaction Partners
The Company�� partnership, through a written agreement, with OpenTable provides consumers the ability to reserve seats directly on the business listing pages of restaurants, which participate in OpenTable�� network. Its partnership, through a written agreement, with Orbitz allows consumers to book rooms directly on the business listing pages of hotels, which affiliate with Orbitz.
The Company competes with Google, Yahoo! and Bing.
Advisors' Opinion:- [By Scott Ryan Anderson]
At this point for investors, subscriber growth would be good to see, but they have already achieved dominance. The growth story now and for the future is the growth in the number of different ways that Facebook can monetize its extraordinary user base. Google's search has strengths that Facebook doesn't have and Facebook has strengths that Google doesn't have, primarily with the ever-growing mobile usage. Google has more to lose and recent quarterly reports demonstrate that Facebook's ad revenue is growing at Google's expense since Facebook is more competitive in mobile thus far. As I pointed out in a column in quarter two, Facebook and Yelp (YELP), two companies very strong in mobile, have seen growth that was almost identical to the number by which Google's ad revenue shrunk during that same quarter.
- [By Alanna Petroff]
The site connects students with companies such as Xerox (XRX, Fortune 500), Kaplan and Yelp (YELP).
Udemy, an online learning platform that uses the site to recruit, said it provided a better caliber of freelance candidate.
- [By Dan Gallagher]
Yahoo (YHOO) � shares were up 2.6% to $34.74. Yelp (YELP) �rose 1.8%.
Hot Defensive Companies To Invest In Right Now: Apache Corporation(APA)
Apache Corporation, together with its subsidiaries, engages in the exploration, development, and production of natural gas, crude oil, and natural gas liquids. The company has exploration and production interests in the Gulf of Mexico, the Gulf Coast, east Texas, the Permian basin, the Anadarko basin, and the Western Sedimentary basin of Canada; and onshore Egypt, offshore Western Australia, offshore the United Kingdom in the North Sea, and onshore Argentina, as well as on the Chilean side of the island of Tierra del Fuego. Apache Corporation sells its natural gas to local distribution companies, utilities, end-users, integrated oil and gas companies, and marketers; and crude oil to integrated oil companies, marketing and transportation companies, and refiners. As of December 31, 2009, it had total estimated proved reserves of 1,067 million barrels of crude oil, condensate, and natural gas liquids, as well as 7.8 trillion cubic feet of natural gas. The company was founded in 1954 and is based in Houston, Texas.
Advisors' Opinion:- [By Rich Duprey]
Oil and gas exploration company�Apache� (NYSE: APA ) will pay a second-quarter dividend of $0.20 per share, the same rate it paid last quarter after raising the payout 17% from $0.17 per share, the company announced today.
Hot Defensive Companies To Invest In Right Now: BioTime Inc (BTX)
BioTime, Inc., incorporated on November 30, 1990, is a biotechnology company focused on the emerging field of regenerative medicine. Its commercial strategy is focused on its line of research products, such as ACTCellerate cell lines and associated ESpan culture media, HyStem hydrogels, human embryonic stem (hES) cell lines, and royalties from Hextend. Its focus is to provide regenerative therapies for age-related degenerative diseases. In January 2011, the Company acquired the assets of Cell Targeting, Inc. (CTI), a biotechnology company focused on methods of painting molecules on the surface of cells, which in turn causes the cells to adhere to particular tissues, such as those afflicted with disease. On March 21, 2011, the Company acquired Glycosan BioSystems, Inc. (Glycosan) through a merger of Glycosan with OrthoCyte Corporation (OrthoCyte). Through the merger, OrthoCyte acquired all of Glycosan�� assets, including Glycosan�� Hystem hydrogel product line. In March 2011, the Company entered into an agreement with XenneX, Inc., pursuant to which it organized LifeMap Sciences, Inc. (LifeMap), a subsidiary formed to advance the development and commercialization of its human embryonic stem (hES) cell data base. In August 2011, four hES cell lines (ESI-035, ESI-049, ESI-051 and ESI-053) developed by its subsidiary ES Cell International (ESI) were approved by the National Institutes of Health (NIH) for inclusion in the NIH Human Embryonic Stem Cell Registry. In May 2012, the Company acquired XenneX, Inc., through a merger of XenneX into LifeMap Sciences. In September 2012, the Company formed a wholly owned subsidiary, BioTime Acquisition Corporation. In October 2013, Geron Corporation announced the closing of the transaction to divest the Company's stem cell assets to Asterias Biotherapeutics, Inc., a subsidiary of BioTime, Inc.
HyStem is a biomaterial, which mimics the human extracellular matrix, which is the network of molecules surrounding cells in organs and tissues which is essent! ial to cellular function. Its HyStem hydrogels may have other applications when combined with the diverse and scalable cell types its scientists have isolated from hES cells. HyStem-Rx is a clinical grade formulation of HyStem-C, a biocompatible, implantable hyaluronan and collagen-based matrix for cell delivery in human clinical applications. Its subsidiary, OncoCyte Corporation, is developing PanC-Dx, a non-invasive blood-based cancer screening test designed to detect the presence of various human cancers, including cancers of the breast, lung, bladder, uterus, stomach, and colon, during routine check -ups. BioTime Asia, Limited (BioTime Asia) sells products for research use and may develop therapies to treat cancer and neurological and orthopedic diseases in Asia. OrthoCyte Corporation (OrthoCyte) is developing therapies to treat orthopedic disorders, diseases and injuries. ReCyte Therapeutics, Inc. (ReCyte Therapeutics) is developing therapies for age-related cardiovascular and blood disorders. Cell Cure Neurosciences Ltd. (Cell Cure Neurosciences), is a biotechnology company focused on developing stem cell-based therapies for retinal and other neurological disorders, including the development of retinal pigment epithelial (RPE) cells for the treatment of age-related macular degeneration. LifeMap Sciences, Inc. (LifeMap) is advancing the development and commercialization of our embryonic stem cell database and plans to make the database available for the marketing of research products and for use by stem cell researchers at pharmaceutical and biotechnology companies and other institutions via paid subscriptions or on a fee per use basis.
The Company�� blood plasma expander product, Hextend, is a physiologically balanced intravenous solution used in the treatment of hypovolemia, a condition caused by low blood volume, often from blood loss during surgery or injury. Hextend maintains circulatory system fluid volume and blood pressure, and keeps vital organs perfused during surgery and t! rauma car! e. Hextend is manufactured and distributed in the United States by Hospira, Inc., and in South Korea by CJ CheilJedang (CJ), under license from it.
Human Embryonic Stem Cell Lines for Research Use
Combined with the Company�� ACTCellerate technology, it derives of a range of markets human embryonic progenitor cells (hEPCs). ESI�� six current good manufacturing practices (cGMP) hES cell lines have been approved by the NIH for inclusion in the Human Embryonic Stem Cell Registry, which renders those cell lines eligible for use in federally funded research. The ESI hES cell lines are available for purchase through www.biotimeinc.com. It also markets hEPCs developed using ACTCellerate technology. Its hEPCs are also available for sale through www.biotimeinc.com. It derived the complete genome sequence of five of the ESI hES cell lines to facilitate the development of products derived from these cell lines. It has made these GMP-grade cell lines, along with certain documentation and complete genomic deoxyribonucleic acid (DNA) sequence information, available for sale.
The Company offers human stem cell products and technology that can be used by researchers at universities and at companies in the bioscience and biopharmaceutical industries. It has developed research and clinical grade hES cell lines, which it markets for both basic research and therapeutic product development. It also markets human embryonic progenitor cell (hEPCs) developed using ACTCellerate technology. These hEPCs are purified lineages of cells, which are intermediate in the developmental process between embryonic stem cells and fully differentiated cells. The ACTCellerate cell lines are also available for purchase through http://www.biotimeinc.com.
Human Embryonic Progenitor Cells
Through the Company�� subsidiary ReCyte Therapeutics, it had a license from Advanced Cell Technology, Inc. (ACT) to use ACTCellerate technology, and the rights to market more than 200 human c! ell types! made using that process. ACTCellerate allows the rapid isolation of hEPCs, which are cells that are intermediate in the developmental process between embryonic stem cells and fully differentiated cells.
Through an agreement with ReCyte Therapeutics, Millipore Corporation became a global distributor of ACTCellerate hEPC lines. In addition to the products, which it is co-marketing with Millipore, it offers 92 other ACTCellerate hEPC lines for purchase at www.biotimeinc.com. Through its subsidiary LifeMap, it provides online biomedical database services to increase awareness of molecular markers and diverse cell types comprising its ACTCellerate hEPC lines. It also focuses to market additional cell types manufactured with its PureStem technology. PureStem cell lines are produced by the exogenous expression of specific transcription factors, which regulate the differentiation of cell types from hES or induced pluripotent stem (iPS) cells. BioTime Asia has an agreement with Shanghai Genext Medical Technology Co., Ltd. to sell ACTCellerate hEPC lines and related ESpan growth media to the medical and biological research communities in China, Taiwan, Hong Kong, and Macau on an exclusive basis. The marketing agreement includes provisions for an initial stocking inventory and annual milestones to maintain exclusivity. The Company�� California Institute of Regenerative Medicine (CIRM)-funded research addresses the need for industrial scale production of purified therapeutic cells.
hES Cells Carrying Genetic Diseases
The Company focuses to add to its product line muscle progenitor cells produced from five hES cell lines carrying genes for Duchenne muscular dystrophy, Emery-Dreifuss muscular dystrophy, spinal muscular atrophy Type I, facioscapulohumeral muscular dystrophy 1A, and Becker muscular dystrophy. It obtained the diseased hES cell lines from Reproductive Genetics Institute (RGI).
ESpan Cell Growth Media
The Company is marketing a range of! cell-gro! wth media products called ESpan. These growth media are optimized for the growth of hEPC types. Cells need to be propagated in liquid media, in both the laboratory setting, where basic research on stem cells is performed, and in the commercial sector. Its ESpan products are marketed through Millipore and Genext.
ESpy Cell Lines
The Company focuses for development of ESpy cell lines. The ability of the ESpy cells to emit light will allow researchers to track the location and distribution of the cells in both in vitro and in vivo studies.
HyStem Hydrogel for Research and HyStem-Rx for Cell Delivery Medical Devices
HyStem is a patented biomaterial that mimics the ECM, the network of molecules surrounding cells in organs and tissues that is essential to cellular function. Its HyStem technology forms the foundation for stem cell delivery products in both the adult and embryonic stem cell marketplace, including products manufactured using its ACTCellerate technology. As an injectable product, HyStem-Rx may address need in cosmetic and reconstructive surgeries and other procedures by transplanting adipose derived cells or other adult stem cells. The transfer of cells in HyStem-Rx localizes the transplanted cells at the intended site and by providing a three-dimensional scaffold upon which cells can rebuild normal tissue. HyStem-Rx may support other emerging cell and tissue transplant therapies, such as those derived from hES and iPS cells, in addition to its potential application in the treatment of a range of conditions such as osteoarthritis, brain tumors, stroke, bone fracture, and wounds.
Advisors' Opinion:- [By John Udovich]
Stem cell stocks have not exactly been the best performers lately in part because the controversy over their use has died down over the years while major breakthroughs have been few or far between, but the industry along with small cap stem cell stocks Pluristem Therapeutics Inc (NASDAQ: PSTI), BioTime, Inc (NYSEMKT: BTX) and BioRestorative Therapies (OTCBB: BRTX) are still quietly producing their share of news or minor breakthroughs worth taking note of. Just consider the following stem cell news or news from small cap players in the sector:
- [By Brian Pacampara]
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotechnology company BioTime (NYSEMKT: BTX ) has received the dreaded one-star ranking.
Hot Defensive Companies To Invest In Right Now: Williams Partners L.P.(WPZ)
Williams Partners L.P. focuses on natural gas transportation, gathering, treating and processing, storage, natural gas liquid fractionation, and oil transportation activities in the United States. The company operates in two segments, Gas Pipeline, and Midstream Gas and Liquids. The Gas Pipeline segment owns and operates approximately 13,900 miles of pipelines with annual throughput of approximately 2,700 trillion British thermal units of natural gas and delivery capacity of approximately 13 million dekatherms of gas. This segment also owns interests in joint venture interstate and intrastate natural gas pipeline systems. The Midstream Gas and Liquids segment includes natural gas gathering, processing, and treating facilities; and crude oil gathering and transportation facilities that serve the producing basins in Colorado, New Mexico, Wyoming, the Gulf of Mexico, and Pennsylvania. Williams Partners GP LLC serves as the general partner of the company. Williams Partners L.P . was founded in 2005 and is based in Tulsa, Oklahoma.
Advisors' Opinion:- [By Dividend]
Here are my most promising stocks from the list:
Williams Partners (WPZ) has a market capitalization of $19.99 billion. The company employs 3,658 people, generates revenue of $7.320 billion and has a net income of $1.232 billion. Williams Partners�� earnings before interest, taxes, depreciation and amortization (EBITDA) amounts to $2.273 billion. The EBITDA margin is 31.05 percent (the operating margin is 20.72 percent and the net profit margin 16.83 percent). - [By The Part-time Investor]
Williams Partners (WPZ), 38 shares at $52.73.
Finally, I had to make some adjustments to my portfolio due to an unexpected tax issue. Through the comments section in response to an article I wrote about some MLPs that passed my criteria, I learned that there are extra tax implications to holding MLPs in a tax deferred retirement portfolio. With this new knowledge I decided to change some of my holdings:
No comments:
Post a Comment